Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial Twenty-eight patients ...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...